14 results about "Roflumilast" patented technology

This method involves treating a patient's skin condition or disease by topically applying a pharmaceutical composition containing roflumilast. Treatment methods include once-daily application of the roflumilast composition for a period of time, followed by twice-weekly application of the roflumilast composition as a maintenance dosing regimen.

The present invention is directed to a method for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and / or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably comprises dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and / or hexylene glycol.

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

Methods of treating a patient suffering from one or more of epidermal disorders of persistent inflammation—cell kinetics and differentiation disorders, epidermal disorders of persistent inflammation—altered reactivity disorders, disorders of the lips, oral, or vaginal mucosa, epidermal disorders of cohesion—vesicular and bullous disorders, cutaneous lymphomas, skin manifestations of rheumatologic diseases, hypomelanoses and hypermelanoses, or skin manifestations related to oncology treatments. The methods include topical administration of a pharmaceutical composition comprising a therapeutically effective amount of roflumilast.

The present invention is directed to an aerosol foam composition comprising roflumilast, an emulsifier blend containing cetearyl alcohol, dicetyl phosphate, and ceteareth-10 phosphate and a hydrocarbon propellant. The aerosol foam composition is preferably an oil in water emulsion. The propellant is a mixture of liquefied hydrocarbon gases preferably a propane / isobutane / butane blend. The hydrocarbon propellant results in an aerosol foam which is stable, has consistent physical properties, excellent aesthetics, and no discernable degradation after long term or accelerated storage conditions.

The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and / or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and / or hexylene glycol.

A method of treating an anterior or vitreous atrial ocular disease by topically administering an ophthalmic pharmaceutical composition of roflumilast to the ocular surface of the eye of a patient. The methods involve topically administering an ophthalmic pharmaceutical composition of roflumilast to the ocular surface of a patient three or four times per day at a higher frequency and higher concentration, the use of which involves a higher concentration and lower frequency dosing regimen compared to other therapeutic regimens, which can provide significant therapeutic activity to the anterior and vitreous atrial chambers of the eye.

Methods of administering ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast, for treating patients with ocular comorbidities of autoimmune disorder, including dry eye disease. The methods include selecting a patient previously diagnosed with an autoimmune disorder and administering an ophthalmic pharmaceutical composition comprising roflumilast to the patient to treat the ocular comorbidity of the autoimmune disorder. The method can result in a reduction of a total lissamine green conjunctival staining score or a reduction in total corneal fluorescein staining score relative to baseline.

Methods of treating anterior or vitreous chamber ocular diseases by administering ophthalmic pharmaceutical compositions of roflumilast topically to the ocular surface of the eye of a patient. The met

An inhalation formulation for treating an IPF disease. The inhalation formulation is an aerosol inhalation liquid formulation, an inhalation aerosol, a dry powder inhaler or a soft mist inhaler. The inhalation formulation contains an active drug, and the active drug is any one of apremilast, ibudilast, roflumilast, crisaborole, and difamilast. A preparation process for the inhalation formulation is introduced into a conventional formulation. An active component in a conventional oral formulation is prone to being destroyed in the digestive tract, and has low bioavailability, a liver first pass effect, and a slow onset of action. An inhalation formulation capable of significantly alleviating IPF is prepared. Tests prove that the prepared inhalation formulation can effectively increase the bioavailability, and improve the clinical use effect.

Methods of administering ophthalmic pharmaceutical formulations of the phosphodiesterase-4 inhibitor, roflumilast, for treating patients with ocular comorbidities of autoimmune disorder, including dry eye disease. The methods include selecting a patient previously diagnosed with an autoimmune disorder and administering an ophthalmic pharmaceutical composition comprising roflumilast to the patient to treat the ocular comorbidity of the autoimmune disorder. The method can result in a reduction of a total lissamine green conjunctival staining score or a reduction in total corneal fluorescein staining score relative to baseline.

Methods for treating diseases of the anterior chamber or vitreous chamber of the eye by topical administration of ophthalmic pharmaceutical compositions containing roflumilast to the ocular surface of a patient. The methods involve the topical administration of ophthalmic pharmaceutical compositions containing roflumilast to the ocular surface of a patient three or four times daily at a higher concentration and with a higher frequency, thereby achieving a significant therapeutic effect on the anterior chamber and vitreous chamber, using dosage regimens with higher concentrations and a lower frequency of administration than other treatment regimens.

A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.

The invention relates to the technical field of medicines, in particular to a compound composition for skin diseases and a preparation method and application thereof. The compound composition for skin diseases comprises the following components in parts by weight: 0.3-2 parts of a phosphodiesterase-4 inhibitor, 5-10 parts of brimonidine microspheres and 5-10 parts of glycerol trioleate, and the phosphodiesterase-4 inhibitor comprises at least one of roflumilast and crisaborole. After the phosphodiesterase-4 inhibitor fully acts, brimonidine is customized into brimonidine microspheres for delayed release of brimonidine and contraction of blood vessels, and the brimonidine microspheres and the early-stage anti-inflammatory action form synergy, so that on one hand, permeation of an inflammatory mediator to tissues is reduced, and on the other hand, metabolic waste transfer is accelerated; therefore, the vicious circle of inflammation-vasodilatation-further inflammation is blocked, and the treatment effect is improved.